🔗 Share this article

As the United States continues making unprecedented changes to its vaccine schedules, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on Covid vaccinations in the pandemic and has concentrated on alleged fatalities following Covid immunization in her short position at the FDA.

Planned Shifts to Childhood Immunization Schedule

Health officials planned to announce major revisions to the childhood vaccination calendar recently, bringing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of step with much of the world with insufficient data for improved outcomes. The announcement has been pushed back until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the meeting. She was recently named interim head of the FDA’s CDER, the fifth individual to run the office this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

Høeg has repeatedly called for halting certain childhood shot schedules in the US in order to be more like the Danish model, a society with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – traditionally the purview of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Expertise

Høeg has no apparent background in drug development, approval processes or management, which has been typical for previous leaders of the CBER. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that prior appointees who ran CBER have had.”

CDER has an enormous workload at the agency, the former commissioner stated.

“Many people just pays attention on the new drug program, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and every single one need to be supervised,” she noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which manages over 5,000 employees. “It is a massive management job, if you execute it properly,” the former official added.

Response and Contentious Policies

Regarding concerns about Høeg’s fitness for the role and whether this assignment indicates more teamwork among regulatory chiefs on vaccines, a press secretary responded that the “inquiries stem from inaccurate presumptions”.

“Her experience matches the functions of her job,” the representative stated, noting the time Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious rapid medication authorization process that reportedly worried her preceding directors. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards laxer oversight of pharmaceuticals, with the exception of immunizations.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, track record, some experts observe. She released a research paper using non-validated crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current federal leadership encompassed changing rules for new vaccines and halting “unnecessary” vaccines, she remarked after the election on a online show. At the FDA, Høeg has allegedly proposed excluding young men from getting Covid vaccines.

“She is an thorough ideologue who starts off with her beliefs and tailors the evidence to accommodate the science in a highly disingenuous, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|